TY - JOUR
T1 - Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
AU - Hollestelle, Antoinette
AU - Nagel, Jord H.A.
AU - Smid, Marcel
AU - Lam, Suzanne
AU - Elstrodt, Fons
AU - Wasielewski, Marijke
AU - Ng, Ser Sue
AU - French, Pim J.
AU - Peeters, Justine K.
AU - Rozendaal, Marieke J.
AU - Riaz, Muhammad
AU - Koopman, Daphne G.
AU - Ten Hagen, Timo L.M.
AU - De Leeuw, Bertie H.C.G.M.
AU - Zwarthoff, Ellen C.
AU - Teunisse, Amina
AU - Van Der Spek, Peter J.
AU - Klijn, Jan G.M.
AU - Dinjens, Winand N.M.
AU - Ethier, Stephen P.
AU - Clevers, Hans
AU - Jochemsen, Aart G.
AU - Den Bakker, Michael A.
AU - Foekens, John A.
AU - Martens, John W.M.
AU - Schutte, Mieke
N1 - Funding Information:
cancers due to differences between ERBB2 protein over-expression, gene amplification and expression of genes from the intrinsic gene set. Our mutation analyses strongly suggested that the basal-like or combined luminal/basal and normal-like or null subtypes of cell lines represent two ends of a spectrum of basal-type breast cancer (Fig. 1). This was supported by the protein expression profiling data, specifically expression of E-cadherin, P-cadherin, N-cadherin, Vimentin and EGFR. Most notable, a similar interrelationship has been proposed for clinical breast cancers [29] and accordingly, Neve et al. [22] had designated these two subtypes of breast cancer cell lines as basal A and basal B. Our molecular characterization of breast cancer cell lines is concordant with the concept that two major types of luminal and basal breast cancers exist that may be subdivided further by protein expression and/or intrinsic gene expression profiling.
PY - 2010/5
Y1 - 2010/5
N2 - Breast cancer has for long been recognized as a highly diverse tumor group, but the underlying genetic basis has been elusive. Here, we report an extensive molecular characterization of a collection of 41 human breast cancer cell lines. Protein and gene expression analyses indicated that the collection of breast cancer cell lines has retained most, if not all, molecular characteristics that are typical for clinical breast cancers. Gene mutation analyses identified 146 oncogenic mutations among 27 well-known cancer genes, amounting to an average of 3.6 mutations per cell line. Mutations in genes from the p53, RB and PI3K tumor suppressor pathways were widespread among all breast cancer cell lines. Most important, we have identified two gene mutation profiles that are specifically associated with luminal-type and basal-type breast cancer cell lines. The luminal mutation profile involved E-cadherin and MAP2K4 gene mutations and amplifications of Cyclin D1, ERBB2 and HDM2, whereas the basal mutation profile involved BRCA1, RB1, RAS and BRAF gene mutations and deletions of p16 and p14ARF. These subtype-specific gene mutation profiles constitute a genetic basis for the heterogeneity observed among human breast cancers, providing clues for their underlying biology and providing guidance for targeted pharmacogenetic intervention in breast cancer patients.
AB - Breast cancer has for long been recognized as a highly diverse tumor group, but the underlying genetic basis has been elusive. Here, we report an extensive molecular characterization of a collection of 41 human breast cancer cell lines. Protein and gene expression analyses indicated that the collection of breast cancer cell lines has retained most, if not all, molecular characteristics that are typical for clinical breast cancers. Gene mutation analyses identified 146 oncogenic mutations among 27 well-known cancer genes, amounting to an average of 3.6 mutations per cell line. Mutations in genes from the p53, RB and PI3K tumor suppressor pathways were widespread among all breast cancer cell lines. Most important, we have identified two gene mutation profiles that are specifically associated with luminal-type and basal-type breast cancer cell lines. The luminal mutation profile involved E-cadherin and MAP2K4 gene mutations and amplifications of Cyclin D1, ERBB2 and HDM2, whereas the basal mutation profile involved BRCA1, RB1, RAS and BRAF gene mutations and deletions of p16 and p14ARF. These subtype-specific gene mutation profiles constitute a genetic basis for the heterogeneity observed among human breast cancers, providing clues for their underlying biology and providing guidance for targeted pharmacogenetic intervention in breast cancer patients.
KW - Breast cancer subtypes
KW - Histological classification
KW - Intrinsic subtypes
KW - Molecular classification
KW - Mutation analysis
UR - http://www.scopus.com/inward/record.url?scp=77951295615&partnerID=8YFLogxK
U2 - 10.1007/s10549-009-0460-8
DO - 10.1007/s10549-009-0460-8
M3 - Article
C2 - 19593635
AN - SCOPUS:77951295615
SN - 0167-6806
VL - 121
SP - 53
EP - 64
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -